Nasdaq btai.

BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ...BTAI's recent financials show a net loss of $53.5MM for 2Q23, with a cash reserve expected to last until mid-2024. Strategic financing negotiations are underway. We maintain a hold rating on ...On track to submit complete NDA in Q1 2021. NEW HAVEN, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage ...Shares of BioXcel Therapeutics ( BTAI -1.80%) were down 62% at 11 a.m. on Thursday after the company announced phase 3 trial results for Alzheimer's disease–related agitation therapy BXCL501 ...

Nov 29, 2023 · According to the issued ratings of 7 analysts in the last year, the consensus rating for BioXcel Therapeutics stock is Hold based on the current 5 hold ratings and 2 buy ratings for BTAI. The average twelve-month price prediction for BioXcel Therapeutics is $23.88 with a high price target of $40.00 and a low price target of $11.00. SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period ...One share of BTAI stock can currently be purchased for approximately $3.89. Is BioXcel Therapeutics, Inc. listed on the NASDAQ or NYSE?

Price. %Change. 3.830. -1.79%. paper trading platform. Webull offers BTAI Ent Holdg (BTAI) historical stock prices, in-depth market analysis, NASDAQ: BTAI real-time stock quote data, in-depth charts, free BTAI options chain data, and a fully built financial calendar to help you invest smart. Buy BTAI stock at Webull.

NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...BioXcel Therapeutics Inc. 4.13. Delayed Data. As of Nov 17. -0.12 / -2.82%. Today’s Change. 2.23. Today ||| 52-Week Range. 34.13.On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days.On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days.Oct 10, 2023 · Investors, who purchased BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares prior to December 2021 and continue to hold any of those NASDAQ: BTAI shares, also have certain options and should contact ...

BioXcel Therapeutics, Inc. Common Stock (BTAI) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary ...

NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...BioXcel Therapeutics Inc (NASDAQ: BTAI)( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s ...Find the latest Earnings Report Date for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.NEW YORK, Dec. 1, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: …

BioXcel Therapeutics, Inc. (BTAI) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 3.9000 +0.0700 (+1.83%) At close: 04:00PM EST. 3.9999 +0.10 (+2.56%) After hours:... NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and ...NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., June 23, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...Price. %Change. 3.830. -1.79%. paper trading platform. Webull offers BTAI Ent Holdg (BTAI) historical stock prices, in-depth market analysis, NASDAQ: BTAI real-time stock quote data, in-depth charts, free BTAI options chain data, and a fully built financial calendar to help you invest smart. Buy BTAI stock at Webull.

The latest price target for . BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on November 15, 2023.The analyst firm set a price target for $11.00 expecting BTAI to rise to ...Fintel reports that on October 5, 2023, Truist Securities downgraded their outlook for BioXcel Therapeutics (NASDAQ:BTAI) from Buy to Hold . Analyst Price Forecast Suggests 650.57% Upside As of ...

BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...Live Short Interest data, Utilization, Cost to borrow and much more for BioXcel Therapeutics, Nasdaq:BTAIView real-time BTAI stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...NEW HAVEN, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel” or the “Company”), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., June 23, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...The latest price target for . BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on November 15, 2023.The analyst firm set a price target for $11.00 expecting BTAI to rise to ...BioXcel Therapeutics (NASDAQ:BTAI), a biopharma company based in Connecticut, leverages AI and machine learning to develop innovative treatments for central nervous system and immuno-oncology ...22 Aug 2023 ... (NASDAQ: BTAI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class ...See the latest BioXcel Therapeutics Inc stock price (BTAI:XNAS), related news, valuation, dividends and more to help you make your investing decisions.May 19, 2021 · NEW HAVEN, Conn., May 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

BTAI support price is $3.53 and resistance is $4.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BTAI stock will trade within this expected range on the day. View a ...

BTAI STOCK Price - BioXcel Therapeutics Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI. NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI). Such investors are …NEW HAVEN, Conn., Jan. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...Oct 31, 2023 · NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ... Source: aslysun / Shutterstock.com. BioXcel Therapeutics (NASDAQ:BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space.Based on its “about us” page, BioXcel is ...Some companies are tagging along, including BioXcel Therapeutics (NASDAQ: BTAI), a small-cap biotech stock. BioXcel remains deep in the red for the year, but ongoing developments have helped fuel ...NEW HAVEN, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced proof-of-concept data from its Phase 1b study of ...BioXcel Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 5,080,000 shares, a decrease of 12.6% from the previous total of 5,810,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a …NEW HAVEN, Conn., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing ...

BioXcel Therapeutics, Inc. (BTAI). NASDAQ: BTAI · IEX Real-Time Price · USD.NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Nov 24, 2023 · BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ... Instagram:https://instagram. vanguard international stock etfsofi stocoptionprofitcalculatorhow much will ssi checks be in 2024 NEW HAVEN, Conn., Feb. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., March 15, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ... microsoft ipobest prop firms for futures The big shareholder groups in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely ...The public float for BTAI is 20.22M, and currently, short sellers hold a 25.11% ratio of that floaft. The average trading volume of BTAI on November 30, 2023 was 3.17M shares. BTAI) stock’s latest price update. BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has dropped by -0.26 in relation to previous closing price of 3.91. hoka stock BioXcel Therapeutics, Inc. (BTAI). NASDAQ: BTAI · IEX Real-Time Price · USD.Alliancebernstein Now Owns 0.10% of BioXcel Therapeutics (BTAI) Feb 9, 2023.NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...